Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @ArrowheadPharma
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ArrowheadPharma
-
Today
$ARWR reported promising interim results from ongoing Ph1/2a studies of our cardiometabolic#RNAi candidates ARO-APOC3 being developed for severe#hypertriglyceridemia & ARO-ANG3 being developed for#dyslipidemias &#MetabolicDiseases. Learn more: http://bit.ly/3bdGvh7 pic.twitter.com/9o74TCFrKs
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today we are hosting a webcast & conference call at 4:30 p.m. EST to discuss our fiscal 2020 Q1
#FinancialResults. The live audio webcast can be accessed on our website at http://bit.ly/2GZXkOI . Conference call details can be found here: http://bit.ly/39dvEBY .$ARWRpic.twitter.com/gN5gUtxmSl
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ArrowheadPharma proslijedio/la je Tweet
Congratulations to
@gourab06 and team@NHS_Lothian recruiting UK's 1st patient to the ARO-AAT 2002 Study, investigating a drug to treat#liver disease due to Alpha-1 Antitrypsin Deficiency@ArrowheadPharma@Alpha1_Global. More on#research in Scotland: http://bit.ly/2ynD6Kh .pic.twitter.com/RMbW11yOzI
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We will host a webcast and conference call at 4:30 p.m. EST on Wednesday, February 5 to discuss our fiscal 2020 Q1
#FinancialResults. See press release for conference call and webcast details: http://bit.ly/36lrq9z$ARWRHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are pleased to welcome James Hassard to the Arrowhead team in the newly-created position of chief commercial officer. Please read the full press release here: http://bit.ly/36viiQC
$ARWRpic.twitter.com/QeKk4Uqabh
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Wishing everyone a
#HappyHolidays and a wonderful#NewYear from the Arrowhead team! We have plenty to look forward to in 2020, including the continued development of our#RNAi therapies for intractable diseases.$ARWRpic.twitter.com/7sWSJfd2RG
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We've dosed the first patient in AROAAT002, an open-label Phase 2 clinical study of ARO-AAT,
$ARWR's second generation#RNAi therapeutic being developed as a treatment for the rare genetic#LiverDisease associated with#AATD. Read more details at:http://bit.ly/2Z9k8DVHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today, we announced
$ARWR filed an application for approval to begin a Phase 1 clinical trial of ARO-HSD, our investigational#RNAi therapeutic being developed as a treatment for alcohol related & nonalcohol related#LiverDiseases, such as#NASH. Read:http://bit.ly/2rIiblUHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We're pleased to welcome Marianne De Backer to
$ARWR's Board of Directors.@MDDBacker is the current Executive VP, Head of Global Business Development & Licensing, and member of the Executive Committee of the Pharmaceuticals division of@BayerPharma. Read: http://bit.ly/2rHK1P2 pic.twitter.com/SOfpddNdHB
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Happy Thanksgiving from the team at Arrowhead! Wishing you and your loved ones a joyous and gratitude-filled holiday.
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
It was a pleasure to participate in the 2019 “Virtual Walk for Alpha-1” hosted by
@AlphaFriend. Our team members based in Pasadena, CA and Madison, WI all joined in to raise awareness during#Alpha1Awareness month!pic.twitter.com/eEPr2iuL7p
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today we are hosting a webcast and conference call at 4:30 PM EDT to discuss our fiscal year end
#FinancialResults. The live audio webcast can be accessed on our website at http://bit.ly/2DvUoIn . Conference call details can be found here: http://bit.ly/34nOkgo$ARWRHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#Alpha1 disease is a rare genetic disorder. It can lead to serious#LiverDisease including#Cirrhosis and#LiverCancer. Check out@Alphafriend’s resources to help raise#Alpha1Awareness: http://bit.ly/2OHrIAT pic.twitter.com/cI1KRixZae
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
At Arrowhead, we’re developing a potential treatment for the
#LiverDisease associated with#Alpha1 antitrypsin deficiency (#AATD). This genetic condition can lead to serious lung disease and/or#LiverDisease. Learn more about#Alpha1Awareness here: http://bit.ly/2KG4F8B pic.twitter.com/X670lhBey0
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today, we presented updated Phase 1 clinical data in two late-breaking oral presentations at
#AHA19 on our cardiometabolic candidates ARO-APOC3 and ARO-ANG3. Read our press release here: http://bit.ly/2OqGjjY and see presentation slides here: http://bit.ly/2DvUoIn#ARWRpic.twitter.com/YabggliQl5
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Heartfelt thanks to Dr. Bruce Given for decades of work bringing important new medicines to patients and a sincere welcome to Dr. Javier San Martin and Dr. Curt Bradshaw who share the same passion for innovation
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
November is
#Alpha1Awareness month.@Alphafriend estimates that at least 100,000 people in the U.S. live with#Alpha1 deficiency. This rare genetic disorder severely damages the liver and lungs. To help raise#Alpha1Awareness, click here: http://bit.ly/33Rsulp pic.twitter.com/50dMXTdmcX
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We will host a webcast and conference call at 4:30 PM EDT on Monday, November 25 to discuss our fiscal year end
#FinancialResults. Please see press release for conference call and webcast details: http://bit.ly/37351Qe$ARWRHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today, Arrowhead and collaborator Janssen announced Phase 2
#HepatitisB data in two poster presentations at@AASLDtweets’s#LiverMtg19. Read our press release here: http://bit.ly/2qBk9Dq and see the posters here: http://bit.ly/2DvUoIn$ARWRHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.